1 5062 157 PHOSPHATE NIMA-RELATED KINASE 2-DEPENDENT EPIGENETIC PATHWAYS IN DORSAL ROOT GANGLION NEURONS MEDIATES PACLITAXEL-INDUCED NEUROPATHIC PAIN. BACKGROUND: THE MICROTUBULE-STABILIZING DRUG PACLITAXEL (PTX) IS AN IMPORTANT CHEMOTHERAPEUTIC AGENT FOR CANCER TREATMENT AND CAUSES PERIPHERAL NEUROPATHY AS A COMMON SIDE EFFECT THAT SUBSTANTIALLY IMPACTS THE FUNCTIONAL STATUS AND QUALITY OF LIFE OF PATIENTS. THE MECHANISTIC ROLE FOR NIMA-RELATED KINASE 2 (NEK2) IN THE PROGRESSION OF PTX-INDUCED NEUROPATHIC PAIN HAS NOT BEEN ESTABLISHED. METHODS: ADULT MALE SPRAGUE-DAWLEY RATS INTRAPERITONEALLY RECEIVED PTX TO INDUCE NEUROPATHIC PAIN. THE PROTEIN EXPRESSION LEVELS IN THE DORSAL ROOT GANGLION (DRG) OF ANIMALS WERE MEASURED BY BIOCHEMICAL ANALYSES. NOCICEPTIVE BEHAVIORS WERE EVALUATED BY VON FREY TESTS AND HOT PLATE TESTS. RESULTS: PTX INCREASED PHOSPHORYLATION OF THE IMPORTANT MICROTUBULE DYNAMICS REGULATOR NEK2 IN DRG NEURONS AND INDUCED PROFOUND NEUROPATHIC ALLODYNIA. PTX-ACTIVATED PHOSPHORYLATED NEK2 (PNEK2) INCREASED JUMONJI DOMAIN-CONTAINING 3 (JMJD3) PROTEIN, A HISTONE DEMETHYLASE PROTEIN, TO SPECIFICALLY CATALYZE THE DEMETHYLATION OF THE REPRESSIVE HISTONE MARK H3 LYSINE 27 TRIMETHYLATION (H3K27ME3) AT THE TRPV1 GENE, THEREBY ENHANCING TRANSIENT RECEPTOR POTENTIAL VANILLOID SUBTYPE-1 (TRPV1) EXPRESSION IN DRG NEURONS. MOREOVER, THE PNEK2-DEPENDENT PTX RESPONSE PROGRAM IS REGULATED BY ENHANCING P90 RIBOSOMAL S6 KINASE 2 (RSK2) PHOSPHORYLATION. CONVERSELY, INTRATHECAL INJECTIONS OF KAEMPFEROL (A SELECTIVE RSK2 ACTIVATION ANTAGONIST), NCL 00017509 (A SELECTIVE NEK2 INHIBITOR), NEK2-TARGETED SIRNA, GSK-J4 (A SELECTIVE JMJD3 INHIBITOR), OR CAPSAZEPINE (AN ANTAGONIST OF TRPV1 RECEPTOR) INTO PTX-TREATED RATS REVERSED NEUROPATHIC ALLODYNIA AND RESTORED SILENCING OF THE TRPV1 GENE, SUGGESTING THE HIERARCHY AND INTERACTION AMONG PHOSPHORYLATED RSK2 (PRSK2), PNEK2, JMJD3, H3K27ME3, AND TRPV1 IN THE DRG NEURONS IN PTX-INDUCED NEUROPATHIC PAIN. CONCLUSIONS: PRSK2/JMJD3/H3K27ME3/TRPV1 SIGNALING IN THE DRG NEURONS PLAYS AS A KEY REGULATOR FOR PTX THERAPEUTIC APPROACHES. 2023 2 5297 77 PROTEIN ARGININE METHYLTRANSFERASE 5 CONTRIBUTES TO PACLITAXEL-INDUCED NEUROPATHIC PAIN BY ACTIVATING TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 EPIGENETIC MODIFICATION IN DORSAL ROOT GANGLION. BACKGROUND: PACLITAXEL (PTX), WHICH IS A FIRST-LINE CHEMOTHERAPY DRUG USED TO TREAT VARIOUS TYPES OF CANCERS, EXHIBITS PERIPHERAL NEUROPATHY AS A COMMON SIDE EFFECT THAT IS DIFFICULT TO TREAT. PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT 5) IS A KEY REGULATOR OF THE CHEMOTHERAPY RESPONSE, AS CHEMOTHERAPY DRUGS INDUCE PRMT5 EXPRESSION. HOWEVER, LITTLE IS KNOWN ABOUT THE PRMT5-MEDIATED EPIGENETIC MECHANISMS INVOLVED IN PTX-INDUCED NEUROPATHIC ALLODYNIA. METHODS: SPRAGUE-DAWLEY RATS WERE INTRAPERITONEALLY GIVEN PTX TO INDUCE NEUROPATHIC PAIN. BIOCHEMICAL ANALYSES WERE CONDUCTED TO MEASURE THE PROTEIN EXPRESSION LEVELS IN THE DORSAL ROOT GANGLION (DRG) OF THE ANIMALS. THE VON FREY TEST AND HOT PLATE TEST WERE USED TO EVALUATE NOCICEPTIVE BEHAVIORS. RESULTS: PTX INCREASED THE PRMT5 (MEAN DIFFERENCE [MD]: 0.68, 95% CONFIDENCE INTERVAL [CI], 0.88-0.48; P < .001 FOR VEHICLE)-MEDIATED DEPOSITION OF HISTONE H3R2 DIMETHYL SYMMETRIC (H3R2ME2S) AT THE TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 (TRPV1) PROMOTER IN THE DRG. PRMT5-INDUCED H3R2ME2S RECRUITED WD REPEAT DOMAIN 5 (WDR5) TO INCREASE TRIMETHYLATION OF LYSINE 4 ON HISTONE H3 (H3K4ME3) AT TRPV1 PROMOTERS, THUS RESULTING IN TRPV1 TRANSCRIPTIONAL ACTIVATION (MD: 0.65, 95% CI, 0.82-0.49; P < .001 FOR VEHICLE) IN DRG IN PTX-INDUCED NEUROPATHIC PAIN. MOREOVER, PTX INCREASED THE ACTIVITY OF NADPH OXIDASE 4 (NOX4) (MD: 0.66, 95% CI, 0.81-0.51; P < .001 FOR VEHICLE), PRMT5-INDUCED H3R2ME2S, AND WDR5-MEDIATED H3K4ME3 IN THE DRG IN PTX-INDUCED NEUROPATHIC PAIN. PHARMACOLOGICAL ANTAGONISM AND THE SELECTIVE KNOCKDOWN OF PRMT5 IN DRG NEURONS COMPLETELY BLOCKED PRMT5-MEDIATED H3R2ME2S, WDR5-MEDIATED H3K4ME3, OR TRPV1 EXPRESSION AND NEUROPATHIC PAIN DEVELOPMENT AFTER PTX INJECTION. REMARKABLY, NOX4 INHIBITION NOT ONLY ATTENUATED ALLODYNIA BEHAVIOR AND REVERSED THE ABOVE-MENTIONED SIGNALING BUT ALSO REVERSED NOX4 UPREGULATION VIA PTX. CONCLUSIONS: THUS, THE NOX4/PRMT5-ASSOCIATED EPIGENETIC MECHANISM IN DRG HAS A DOMINANT FUNCTION IN THE TRANSCRIPTIONAL ACTIVATION OF TRPV1 IN PTX-INDUCED NEUROPATHIC PAIN. 2023 3 4919 37 PANNEXIN-1 UP-REGULATION IN THE DORSAL ROOT GANGLION CONTRIBUTES TO NEUROPATHIC PAIN DEVELOPMENT. PANNEXIN-1 (PANX1) IS A LARGE-PORE MEMBRANE CHANNEL INVOLVED IN THE RELEASE OF ATP AND OTHER SIGNALING MEDIATORS. LITTLE IS KNOWN ABOUT THE EXPRESSION AND FUNCTIONAL ROLE OF PANX1 IN THE DORSAL ROOT GANGLION (DRG) IN THE DEVELOPMENT OF CHRONIC NEUROPATHIC PAIN. IN THIS STUDY, WE DETERMINED THE EPIGENETIC MECHANISM INVOLVED IN INCREASED PANX1 EXPRESSION IN THE DRG AFTER NERVE INJURY. SPINAL NERVE LIGATION IN RATS SIGNIFICANTLY INCREASED THE MRNA AND PROTEIN LEVELS OF PANX1 IN THE DRG BUT NOT IN THE SPINAL CORD. IMMUNOCYTOCHEMICAL LABELING SHOWED THAT PANX1 WAS PRIMARILY EXPRESSED IN A SUBSET OF MEDIUM AND LARGE DRG NEURONS IN CONTROL RATS AND THAT NERVE INJURY MARKEDLY INCREASED THE NUMBER OF PANX1-IMMUNOREACTIVE DRG NEURONS. NERVE INJURY SIGNIFICANTLY INCREASED THE ENRICHMENT OF TWO ACTIVATING HISTONE MARKS (H3K4ME2 AND H3K9AC) AND DECREASED THE OCCUPANCY OF TWO REPRESSIVE HISTONE MARKS (H3K9ME2 AND H3K27ME3) AROUND THE PROMOTER REGION OF PANX1 IN THE DRG. HOWEVER, NERVE INJURY HAD NO EFFECT ON THE DNA METHYLATION LEVEL AROUND THE PANX1 PROMOTER IN THE DRG. FURTHERMORE, INTRATHECAL INJECTION OF THE PANX1 BLOCKERS OR PANX1-SPECIFIC SIRNA SIGNIFICANTLY REDUCED PAIN HYPERSENSITIVITY INDUCED BY NERVE INJURY. IN ADDITION, SIRNA KNOCKDOWN OF PANX1 EXPRESSION IN A DRG CELL LINE SIGNIFICANTLY REDUCED CASPASE-1 RELEASE INDUCED BY NEURONAL DEPOLARIZATION. OUR FINDINGS SUGGEST THAT NERVE INJURY INCREASES PANX1 EXPRESSION LEVELS IN THE DRG THROUGH ALTERED HISTONE MODIFICATIONS. PANX1 UP-REGULATION CONTRIBUTES TO THE DEVELOPMENT OF NEUROPATHIC PAIN AND STIMULATION OF INFLAMMASOME SIGNALING. 2015 4 3368 44 HISTONE METHYLTRANSFERASE G9A DIMINISHES EXPRESSION OF CANNABINOID CB(1) RECEPTORS IN PRIMARY SENSORY NEURONS IN NEUROPATHIC PAIN. TYPE 1 CANNABINOID RECEPTORS (CB(1)RS) ARE EXPRESSED IN THE DORSAL ROOT GANGLION (DRG) AND CONTRIBUTE TO THE ANALGESIC EFFECT OF CANNABINOIDS. HOWEVER, THE EPIGENETIC MECHANISM REGULATING THE EXPRESSION OF CB(1)RS IN NEUROPATHIC PAIN IS UNKNOWN. G9A (ENCODED BY THE EHMT2 GENE), A HISTONE 3 AT LYSINE 9 METHYLTRANSFERASE, IS A KEY CHROMATIN REGULATOR RESPONSIBLE FOR GENE SILENCING. IN THIS STUDY, WE DETERMINED G9A'S ROLE IN REGULATING CB(1)R EXPRESSION IN THE DRG AND IN CB(1)R-MEDIATED ANALGESIC EFFECTS IN AN ANIMAL MODEL OF NEUROPATHIC PAIN. WE SHOW THAT NERVE INJURY PROFOUNDLY REDUCED MRNA LEVELS OF CB(1)RS BUT INCREASED THE EXPRESSION OF CB(2) RECEPTORS IN THE RAT DRG. CHIP RESULTS INDICATED INCREASED ENRICHMENT OF HISTONE 3 AT LYSINE 9 DIMETHYLATION, A G9A-CATALYZED REPRESSIVE HISTONE MARK, AT THE PROMOTER REGIONS OF THE CB(1)R GENES. G9A INHIBITION IN NERVE-INJURED RATS NOT ONLY UP-REGULATED THE CB(1)R EXPRESSION LEVEL IN THE DRG BUT ALSO POTENTIATED THE ANALGESIC EFFECT OF A CB(1)R AGONIST ON NERVE INJURY-INDUCED PAIN HYPERSENSITIVITY. FURTHERMORE, IN MICE LACKING EHMT2 IN DRG NEURONS, NERVE INJURY FAILED TO REDUCE CB(1)R EXPRESSION IN THE DRG AND TO DECREASE THE ANALGESIC EFFECT OF THE CB(1)R AGONIST. MOREOVER, NERVE INJURY DIMINISHED THE INHIBITORY EFFECT OF THE CB(1)R AGONIST ON SYNAPTIC GLUTAMATE RELEASE FROM PRIMARY AFFERENT NERVES TO SPINAL CORD DORSAL HORN NEURONS IN WT MICE BUT NOT IN MICE LACKING EHMT2 IN DRG NEURONS. OUR FINDINGS REVEAL THAT NERVE INJURY DIMINISHES THE ANALGESIC EFFECT OF CB(1)R AGONISTS THROUGH G9A-MEDIATED CB(1)R DOWN-REGULATION IN PRIMARY SENSORY NEURONS. 2020 5 1318 38 DEMETHYLATION OF G-PROTEIN-COUPLED RECEPTOR 151 PROMOTER FACILITATES THE BINDING OF KRUPPEL-LIKE FACTOR 5 AND ENHANCES NEUROPATHIC PAIN AFTER NERVE INJURY IN MICE. G-PROTEIN-COUPLED RECEPTORS ARE CONSIDERED TO BE CELL-SURFACE SENSORS OF EXTRACELLULAR SIGNALS, THEREBY HAVING A CRUCIAL ROLE IN SIGNAL TRANSDUCTION AND BEING THE MOST FRUITFUL TARGETS FOR DRUG DISCOVERY. G-PROTEIN-COUPLED RECEPTOR 151 (GPR151) WAS REPORTED TO BE EXPRESSED SPECIFICALLY IN THE HABENULAR AREA. HERE WE REPORT THE EXPRESSION AND THE EPIGENETIC REGULATION OF GRP151 IN THE SPINAL CORD AFTER SPINAL NERVE LIGATION (SNL) AND THE CONTRIBUTION OF GPR151 TO NEUROPATHIC PAIN IN MALE MICE. SNL DRAMATICALLY INCREASED GPR151 EXPRESSION IN SPINAL NEURONS. GPR151 MUTATION OR SPINAL INHIBITION BY SHRNA ALLEVIATED SNL-INDUCED MECHANICAL ALLODYNIA AND HEAT HYPERALGESIA. INTERESTINGLY, THE CPG ISLAND IN THE GPR151 GENE PROMOTER REGION WAS DEMETHYLATED, THE EXPRESSION OF DNA METHYLTRANSFERASE 3B (DNMT3B) WAS DECREASED, AND THE BINDING OF DNMT3B WITH GPR151 PROMOTER WAS REDUCED AFTER SNL. OVEREXPRESSION OF DNMT3B IN THE SPINAL CORD DECREASED GPR151 EXPRESSION AND ATTENUATED SNL-INDUCED NEUROPATHIC PAIN. FURTHERMORE, KRUPPEL-LIKE FACTOR 5 (KLF5), A TRANSCRIPTIONAL FACTOR OF THE KLF FAMILY, WAS UPREGULATED IN SPINAL NEURONS, AND THE BINDING AFFINITY OF KLF5 WITH GPR151 PROMOTER WAS INCREASED AFTER SNL. INHIBITION OF KLF5 REDUCED GPR151 EXPRESSION AND ATTENUATED SNL-INDUCED PAIN HYPERSENSITIVITY. FURTHER MRNA MICROARRAY ANALYSIS REVEALED THAT MUTATION OF GPR151 REDUCED THE EXPRESSION OF A VARIETY OF PAIN-RELATED GENES IN RESPONSE TO SNL, ESPECIALLY MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) SIGNALING PATHWAY-ASSOCIATED GENES. THIS STUDY REVEALS THAT GPR151, INCREASED BY DNA DEMETHYLATION AND THE ENHANCED INTERACTION WITH KLF5, CONTRIBUTES TO THE MAINTENANCE OF NEUROPATHIC PAIN VIA INCREASING MAPK PATHWAY-RELATED GENE EXPRESSION.SIGNIFICANCE STATEMENT G-PROTEIN-COUPLED RECEPTORS (GPCRS) ARE TARGETS OF VARIOUS CLINICALLY APPROVED DRUGS. HERE WE REPORT THAT SNL INCREASED GPR151 EXPRESSION IN THE SPINAL CORD, AND MUTATION OR INHIBITION OF GPR151 ALLEVIATED SNL-INDUCED NEUROPATHIC PAIN. IN ADDITION, SNL DOWNREGULATED THE EXPRESSION OF DNMT3B, WHICH CAUSED DEMETHYLATION OF GPR151 GENE PROMOTER, FACILITATED THE BINDING OF TRANSCRIPTIONAL FACTOR KLF5 WITH THE GPR151 PROMOTER, AND FURTHER INCREASED GPR151 EXPRESSION IN SPINAL NEURONS. THE INCREASED GPR151 MAY CONTRIBUTE TO THE PATHOGENESIS OF NEUROPATHIC PAIN VIA ACTIVATING MAPK SIGNALING AND INCREASING PAIN-RELATED GENE EXPRESSION. OUR STUDY REVEALS AN EPIGENETIC MECHANISM UNDERLYING GPR151 EXPRESSION AND SUGGESTS THAT TARGETING GPR151 MAY OFFER A NEW STRATEGY FOR THE TREATMENT OF NEUROPATHIC PAIN. 2018 6 532 30 ASTROCYTIC C-JUN N-TERMINAL KINASE-HISTONE DEACETYLASE-2 CASCADE CONTRIBUTES TO GLUTAMATE TRANSPORTER-1 DECREASE AND MECHANICAL ALLODYNIA FOLLOWING PERIPHERAL NERVE INJURY IN RATS. DECREASE OF GLUTAMATE TRANSPORTER-1 (GLT-1) IN THE SPINAL DORSAL HORN AFTER NERVE INJURY INDUCES ENHANCED EXCITATORY TRANSMISSION AND CAUSES PERSISTENT PAIN. HISTONE DEACETYLASES (HDACS)-CATALYZED DEACETYLATION MIGHT CONTRIBUTE TO THE DECREASE OF GLT-1, WHILE THE DETAILED MECHANISMS HAVE YET TO BE FULLY ELABORATED. SPINAL NERVE LIGATION (SNL) INDUCED SIGNIFICANT INCREASES OF HDAC2 AND DECREASES OF GLT-1 IN SPINAL ASTROCYTES. INTRATHECAL INFUSION OF THE HDAC2 INHIBITORS ATTENUATED THE DECREASE OF GLT-1 AND ENHANCED PHOSPHORYLATION OF GLUTAMATE RECEPTORS. GLT-1 AND PHOSPHORYLATED C-JUN N-TERMINAL KINASE (JNK) WERE HIGHLY COLOCALIZED IN THE SPINAL CORD, AND A LARGE NUMBER OF PJNK POSITIVE CELLS WERE HDAC2 POSITIVE. INTRATHECALLY INFUSION OF THE JNK INHIBITOR SP600125 SIGNIFICANTLY INHIBITED SNL-INDUCED UPREGULATION OF HDAC2. SNL-INDUCED HDAC2 UP-REGULATION COULD BE INHIBITED BY THE NEUTRALIZING ANTI-TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) BINDING PROTEIN ETANERCEPT OR THE MICROGLIAL INHIBITOR MINOCYCLINE. IN CULTURED ASTROCYTES, TNF-ALPHA INDUCED ENHANCED PHOSPHORYLATION OF JNK AND A SIGNIFICANT INCREASE OF HDAC2, AS WELL AS A REMARKABLE DECREASE OF GLT-1, WHICH COULD BE PREVENTED BY SP600125 OR THE HDAC2 SPECIFIC INHIBITOR CAY10683. OUR DATA SUGGEST THAT ASTROCYTIC JNK-HDAC2 CASCADE CONTRIBUTES TO GLT-1 DECREASE AND MECHANICAL ALLODYNIA FOLLOWING PERIPHERAL NERVE INJURY. NEUROIMMUNE ACTIVATION AFTER PERIPHERAL NERVE INJURY COULD INDUCE EPIGENETIC MODIFICATION CHANGES IN ASTROCYTES AND CONTRIBUTE TO CHRONIC PAIN MAINTENANCE. 2021 7 5692 28 SILENCING OF LNCRNA PKIA-AS1 ATTENUATES SPINAL NERVE LIGATION-INDUCED NEUROPATHIC PAIN THROUGH EPIGENETIC DOWNREGULATION OF CDK6 EXPRESSION. NEUROPATHIC PAIN (NP) IS AMONG THE MOST INTRACTABLE COMORBIDITIES OF SPINAL CORD INJURY. DYSREGULATION OF NON-CODING RNAS HAS ALSO BEEN IMPLICATED IN THE DEVELOPMENT OF NEUROPATHIC PAIN. HERE, WE IDENTIFIED A NOVEL LNCRNA, PKIA-AS1, BY USING LNCRNA ARRAY ANALYSIS IN SPINAL CORD TISSUE OF SPINAL NERVE LIGATION (SNL) MODEL RATS, AND INVESTIGATED THE ROLE OF PKIA-AS1 IN SNL-MEDIATED NEUROPATHIC PAIN. WE OBSERVED THAT PKIA-AS1 WAS SIGNIFICANTLY UPREGULATED IN SNL MODEL RATS AND THAT PKIA-AS1 KNOCKDOWN ATTENUATED NEUROPATHIC PAIN PROGRESSION. ALTERNATIVELY, OVEREXPRESSION OF PKIA-AS1 WAS SUFFICIENT TO INDUCE NEUROPATHIC PAIN-LIKE SYMPTOMS IN UNINJURED RATS. WE ALSO FOUND THAT PKIA-AS1 MEDIATED SNL-INDUCED NEUROPATHIC PAIN BY DIRECTLY REGULATING THE EXPRESSION AND FUNCTION OF CDK6, WHICH IS ESSENTIAL FOR THE INITIATION AND MAINTENANCE OF NEUROINFLAMMATION AND NEUROPATHIC PAIN. THEREFORE, OUR STUDY IDENTIFIES PKIA-AS1 AS A NOVEL THERAPEUTIC TARGET FOR NEUROINFLAMMATION RELATED NEUROPATHIC PAIN. 2019 8 5401 48 REDUCTION OF SIRT1 EPIGENETICALLY UPREGULATES NALP1 EXPRESSION AND CONTRIBUTES TO NEUROPATHIC PAIN INDUCED BY CHEMOTHERAPEUTIC DRUG BORTEZOMIB. BACKGROUND: BORTEZOMIB IS A FREQUENTLY USED CHEMOTHERAPEUTIC DRUG FOR THE TREATMENT OF MULTIPLE MYELOMA AND OTHER NONSOLID MALIGNANCIES. ACCUMULATING EVIDENCE HAS DEMONSTRATED THAT BORTEZOMIB-INDUCED PERSISTENT PAIN SERVES AS THE MOST FREQUENT REASON FOR TREATMENT DISCONTINUATION. METHODS: THE VON FREY TEST WAS PERFORMED TO EVALUATE NEUROPATHIC PAIN BEHAVIOR, AND REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, CHROMATIN IMMUNOPRECIPITATION, WESTERN BLOT, IMMUNOHISTOCHEMISTRY, AND SMALL INTERFERING RNA WERE PERFORMED TO EXPLORE THE MOLECULAR MECHANISMS IN ADULT MALE SPRAGUE-DAWLEY RATS. RESULTS: WE FOUND THAT APPLICATION OF BORTEZOMIB SIGNIFICANTLY INCREASED THE EXPRESSION OF NALP1 PROTEIN AND MRNA LEVELS IN SPINAL DORSAL HORN NEURONS, AND INTRATHECAL APPLICATION OF NALP1 SIRNA ATTENUATED THE BORTEZOMIB-INDUCED MECHANICAL ALLODYNIA. IN ADDITION, BORTEZOMIB ALSO DECREASED THE SIRT1 EXPRESSION, AND TREATMENT WITH SIRT1 ACTIVATOR RESVERATROL AMELIORATED THE NALP1 UPREGULATION AND MECHANICAL ALLODYNIA INDUCED BY BORTEZOMIB. MEANWHILE, KNOCKDOWN OF SIRT1 USING THE SIRT1 SIRNA INDUCED THE NALP1 UPREGULATION IN DORSAL HORN AND MECHANICAL ALLODYNIA IN NORMAL ANIMAL. THESE RESULTS SUGGESTED THAT REDUCTION OF SIRT1 INDUCED THE NALP1 UPREGULATION IN DORSAL HORN NEURONS, AND PARTICIPATED IN BORTEZOMIB-INDUCED MECHANICAL ALLODYNIA. IMPORTANTLY, WE FOUND THAT THE BINDING OF SIRT1 AND NALP1 PROMOTER REGION DID NOT CHANGE BEFORE AND AFTER BORTEZOMIB TREATMENT, BUT SIRT1 DOWNREGULATION INCREASED P-STAT3 EXPRESSION. FURTHERMORE, THE ACTIVATION OF STAT3 ENHANCED THE RECRUITMENT OF P-STAT3 TO THE NALP1 GENE PROMOTER, WHICH INCREASED THE ACETYLATION OF HISTONE H3 AND H4 IN NALP1 PROMOTER REGIONS AND EPIGENETICALLY UPREGULATED NALP1 EXPRESSION IN THE RODENTS WITH BORTEZOMIB TREATMENT. CONCLUSION: THESE FINDINGS SUGGESTED A NEW EPIGENETIC MECHANISM FOR NALP1 UPREGULATION INVOLVING SIRT1 REDUCTION AND SUBSEQUENT STAT3-MEDIATED HISTONE HYPERACETYLATION IN NALP1 PROMOTER REGION IN DORSAL HORN NEURONS, WHICH CONTRIBUTED TO THE BORTEZOMIB-INDUCED MECHANICAL ALLODYNIA. 2018 9 6148 43 THE EXPRESSION OF TRANSCRIPTION FACTORS MECP2 AND CREB IS MODULATED IN INFLAMMATORY PELVIC PAIN. EARLY ACTIVATION OF TRANSCRIPTION FACTORS IS ONE OF THE EPIGENETIC MECHANISMS CONTRIBUTING TO THE INDUCTION AND MAINTENANCE OF CHRONIC PAIN STATES. PREVIOUS STUDIES IDENTIFIED THE CHANGES IN A NUMBER OF NOCICEPTION-RELATED GENES, SUCH AS CALCITONIN GENE-RELATED PEPTIDE (CGRP), SUBSTANCE P (SP), AND BRAIN-DERIVED NEUROTROPIC FACTOR (BDNF) IN THE PELVIC ORGANS AFTER TRANSIENT COLONIC INFLAMMATION. THE GENE AND PROTEIN EXPRESSION OF THESE NEUROPEPTIDES COULD BE MODULATED BY TRANSCRIPTION FACTORS METHYL-CPG-BINDING PROTEIN 2 (MECP2) AND CAMP RESPONSE ELEMENT-BINDING PROTEIN (CREB). IN THIS STUDY, WE AIMED TO EVALUATE TIME-DEPENDENT CHANGES IN THE EXPRESSION LEVELS OF MECP2 AND CREB IN THE LUMBOSACRAL (LS) SPINAL CORD AND SENSORY GANGLIA AFTER INFLAMMATION-INDUCED PELVIC PAIN IN RAT. ADULT SPRAGUE-DAWLEY RATS WERE TREATED WITH 2,4,6-TRINITROBENZENESULFONIC ACID (TNBS) TO INDUCE TRANSIENT COLONIC INFLAMMATION. LS (L6-S2) SPINAL CORD SEGMENTS AND RESPECTIVE DORSAL ROOT GANGLIAS (DRGS) WERE ISOLATED FROM CONTROL AND EXPERIMENTAL ANIMALS AT 1, 2, 6, 24 H AND 3 DAYS POST-TNBS TREATMENT. IMMUNOHISTOCHEMICAL (IHC) LABELING AND WESTERN BLOTTING EXPERIMENTS WERE PERFORMED TO ASSESS THE EXPRESSION OF MECP2, CREB AND THEIR PHOSPHORYLATED FORMS. TOTAL MECP2 EXPRESSION, BUT NOT PHOSPHORYLATED P-MECP2 (PS421MECP2) EXPRESSION WAS DETECTED IN THE CELLS OF THE SPINAL DORSAL HORN UNDER CONTROL CONDITIONS. COLONIC INFLAMMATION TRIGGERED A SIGNIFICANT DECREASE IN THE NUMBER OF MECP2-EXPRESSING NEURONS IN PARALLEL WITH ELEVATED NUMBERS OF PS421MECP2-EXPRESSING CELLS AT 2 H AND 6 H POST-TNBS. THE MAJORITY OF MECP2-POSITIVE CELLS (80 +/- 6%) CO-EXPRESSED CREB. TNBS TREATMENT CAUSED A TRANSIENT UP-REGULATION OF CREB-EXPRESSING CELLS AT 1 H POST-TNBS ONLY. THE NUMBER OF CELLS EXPRESSING PHOSPHORYLATED CREB (PS133CREB) DID NOT CHANGE AT 1 H AND 2 H POST-TNBS, BUT WAS DOWN-REGULATED BY THREE FOLDS AT 6 H POST-TNBS. ANALYSIS OF DRG SECTIONS REVEALED THAT THE NUMBER OF MECP2-POSITIVE NEURONS WAS UP-REGULATED BY TNBS TREATMENT, REACHING THREE-FOLD INCREASE AT 2 H POST-TNBS, AND EIGHT-FOLD INCREASE AT 6 H POST-TNBS (P